Digest Network Come funziona
Network
/
Società
Pr
Non verificato

Precision BioSciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

65 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Sanità
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Biologia
Igiene alimentare
Salute
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
09/03/2026
Eventi
Industria
Tecnica
Biotecnologia
Igiene alimentare
Tecnologie Varie
Salute
Sanità
Farmaceutica
Biologia
Scienza
HIV, AIDS e malattie autoimmuni
Fitness
Medicina - Varie
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
02/03/2026
Sanità
Tecnologie Varie
Scienza
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Biologia
Fitness
Odontoiatria
Tecnica
Medicina - Varie
Igiene alimentare
Pallavolo
Sport
Salute
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Igiene alimentare
Tecnica
Tecnologie Varie
Biologia
Farmaceutica
Biotecnologia
Medicina - Varie
Cardiologia
Scienza
Salute
Eventi
Industria
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
11/02/2026
Industria
Tecnica
Biotecnologia
Igiene alimentare
Tecnologie Varie
Salute
Sanità
Farmaceutica
Biologia
Scienza
Medicina - Varie
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Biotecnologia
Medicina - Varie
Biologia
Farmaceutica
Salute
Industria
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
23/12/2025
Biologia
Biotecnologia
Tecnica
Salute
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Tecnologie Varie
Medicina - Varie
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
19/11/2025
Biotecnologia
Salute
Medicina - Varie
Eventi
Industria
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Igiene alimentare
Sanità
Tecnica
Tecnologie Varie
Biologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Fitness
Medicina - Varie
Scienza
Salute
Finanza
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Igiene alimentare
Sanità
Tecnica
Tecnologie Varie
Biologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Biotecnologia
Fitness
Medicina - Varie
Scienza
Salute
Fiere
Eventi
Web e Social Network
Telefonia e Varie
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
Fonte
Precision BioSciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0